Atara Biotherapeutics

ATRA · NASDAQ

$9.16+$0.20 (+2.23%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.96

ATRA analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy1
Hold1
Underperform0
Sell0

12-month price target · 5 analysts

Average $13.94 (+52.2% upside)

Low: $10.10
Now: $9.16
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

ATRA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Freedom Broker	May 18, 2026	Upgrade	Sell → Hold	$4.00 → $10.00	45%
Canaccord Genuity	May 8, 2026	Upgrade	Hold → Buy	$6.00 → $13.00	35%
Freedom Broker	Jan 21, 2026	Downgrade	Buy → Sell	$16.00 → $4.00	45%
Canaccord Genuity	Jan 13, 2026	Downgrade	Buy → Hold	$25.00 → $6.00	35%
Canaccord Genuity	Dec 19, 2025	Maintains	Buy	$17.00 → $25.00	35%

The case for and against

Updated Jun 9, 2026

Bull case

Atara Biotherapeutics is a clinical-stage biotechnology company operating in the United States healthcare sector with a focus on developing transformative therapies for serious diseases. Despite clinical risks, Atara's T-cell programs have the potential for accelerated FDA approval based on positive clinical data and longer follow-up periods for patients. Additionally, recent measures taken to address issues with their contract drug manufacturing organization and receipt of a $40M milestone payment provide much-needed cash for the company's next phase of development, particularly in autoimmune diseases. The company's differentiated allogeneic approach may also be better equipped to address the complexities and hesitation associated with autologous CAR T therapies, further supporting a positive outlook for the stock.

Bear case

Atara Biotherapeutics is facing significant challenges with their lead product candidate, Tab-cel, as the FDA has deemed the current data insufficient to support accelerated approval and a new randomized trial would be difficult to enroll patients in and take years to complete. This could have a significant impact on the company's ability to secure necessary funds and continue the program. Additionally, the company is facing financial risks due to having no current revenues and needing to raise significant capital, as well as extensive intellectual property risks and potential competition in the highly competitive biotechnology sector.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.